Pharma BD Deal Intelligence
Teva's 1995 acquisition of Hungary's Biogal Gyogyszergyar planted its flag in Eastern European generics manufacturing right as the region privatized—a modest, unpriced deal that quietly built the manufacturing base Teva's global generics scale-up would later depend on.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Teva Pharmaceutical Industries acquired Hungary's Biogal Gyogyszergyar in 1995, expanding its generic pharmaceutical manufacturing footprint into Eastern Europe in a post-privatization acquisition. The deal strengthened Teva's European generics portfolio and manufacturing base.
Teva/Biogal Active Pharmaceutical Ingredients (API) is a manufacturing capability acquisition, not a disease-treating asset. API competitive landscape is at the contract-manufacturer level: Teva API (combined), Dr. Reddy's, Cipla, Lupin, Aurobindo, Hikma, Mylan API, Piramal. No disease-specific competitive landscape applies.
Teva acquired Biogal, Hungarian generics company, for Eastern European expansion. $13B value likely overstated.
Biogal fully integrated into Teva global generics manufacturing, providing Eastern European capacity.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical (this deal) | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
| Teva Pharmaceutical Industries Ltd. / Barr Pharmaceuticals | 2008 | $7.5B | 58 |
← Browse all deals · How we score deals
More: 1995 deals · Teva Pharmaceutical Industries Ltd. deals · Neurology deals